A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

This study is testing a drug called IBI343 — an antibody-drug conjugate that delivers cancer-killing chemotherapy directly to cancer cells that carry a specific surface protein called Claudin 18.2 — versus a placebo, in people with advanced pancreatic cancer that has not responded to prior treatments. **You may be eligible if...** - You have been diagnosed with unresectable (cannot be surgically removed) or metastatic pancreatic cancer - Your tumor has tested positive for Claudin 18.2 (a protein on cancer cells the drug targets) - You have already received at least two prior chemotherapy regimens, including one fluorouracil-based and one gemcitabine-based regimen, and the cancer progressed - You are in reasonably good physical condition (ECOG score 0 or 2) - Your blood counts and organ function are in an acceptable range **You may NOT be eligible if...** - You have previously received a topoisomerase inhibitor-based antibody-drug conjugate treatment - You have active brain metastases causing symptoms - You are currently participating in another interventional clinical trial - You have had another active primary cancer recently Talk to your doctor to see if this trial is right for you.